Market Research Logo

Global Vasculitis Treatment Market 2017-2021

Global Vasculitis Treatment Market 2017-2021

About Vasculitis Treatment

Vasculitis is an autoimmune disorder that causes inflammation of the blood vessels. The body's immune system attacks the blood vessels, which results in inflammation. When this inflammation occurs, the walls of the affected blood vessels get thicker and the passages through which the blood flows get narrower, which reduces the amount of blood and oxygen delivered to vital organs.

Technavio’s analysts forecast the global vasculitis treatment market to grow at a CAGR of 4.20 % during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global vasculitis treatment market for 2017-2021. To calculate the market size, the report considers the sales from the drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Vasculitis Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Bristol-Myers Squibb
  • CELGENE
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
Other prominent vendors
  • Ablynx
  • AB SCIENCES
  • Acorda Therapeutics
  • Alder Biopharmaceuticals
  • Antares Pharma
  • Astellas Pharma
  • AstraZeneca
  • Baxter
  • Boehringer Ingelhein
  • Can-Fite BioPharma
  • Celltrion
  • ChemoCentryx
  • Coherus BioSciences
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Gilead Sciences
  • Hospira
  • Idera
  • Immunomedics
  • ImmuPharma
  • Incyte
  • Invion
  • KaloBios Pharmaceuticals
  • Lexicon Pharmaceuticals
  • Merck
  • MedImmune
  • Morphotek
  • Novo Nordisk
  • Novartis
  • Opexa Therapeutics
  • Principia
  • Regeneron
  • Sandoz
  • Sanofi
  • Santarus
  • Takeda
  • UCB
  • Vaccinex
  • Vertex Pharmaceuticals
  • Vitae Pharmaceuticals
Market driver
  • Promising pipeline
  • For a full, detailed list, view our report
Market challenge
  • Loss of patent exclusivity of branded therapies
  • For a full, detailed list, view our report
Market trend
  • Strategic alliances
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Vasculitis Treatment Market 2017-2021

Technavio recognizes the following companies as the key players in the global vasculitis treatment market: Bristol-Myers Squibb, CELGENE, F. Hoffmann-La Roche, and GlaxoSmithKline.

Other Prominent Vendors in the market are: Ablynx, AB SCIENCES, Acorda Therapeutics, Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, AstraZeneca, Baxter, Boehringer Ingelhein, Can-Fite BioPharma, Celltrion, ChemoCentryx, Coherus BioSciences, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, Hospira, Idera, Immunomedics, ImmuPharma, Incyte, Invion, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Merck, MedImmune, Morphotek, Novo Nordisk, Novartis, Opexa Therapeutics, Principia, Regeneron, Sandoz, Sanofi, Santarus, Takeda, UCB, Vaccinex, Vertex Pharmaceuticals, and Vitae Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is strategic alliances. Strategic alliances, formed in terms of licensing and collaboration, help in the co-development and commercialization of drugs in different regions. Such agreements ensure the in-flow of adequate funds from both the companies and help to reduce liability costs for individual companies in the case of failures and thereby, attract more venture investments.”

According to the report, one of the major drivers for this market is Promising pipeline. The market shows attractive growth opportunities for vendors globally because of the growing incidences of vasculitis and the rise in the aging population. The clinical drugs pipeline for vasculitis treatment is strong with several emerging therapies, featuring candidates in different stages of development, including first-in-class drugs with disease-modifying properties and better safety and efficacy profiles.

Further, the report states that one of the major factors hindering the growth of this market is loss of patent exclusivity of branded therapies. Expiry of patents results in the loss of exclusivity of that specific drug, leading to a rapid decline in its sales. This is expected to have a negative impact on the revenue of branded drugs used to treat vasculitis. In addition, the entry of generic versions of drugs will lead to a further loss of revenue for the drug manufacturers and hinder the growth of the market.

Companies Mentioned

Bristol-Myers Squibb, CELGENE, F. Hoffmann-La Roche, and GlaxoSmithKline.Other Prominent Vendors in the market are: Ablynx, AB SCIENCES, Acorda Therapeutics, Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, AstraZeneca, Baxter, Boehringer Ingelhein, Can-Fite BioPharma, Celltrion, ChemoCentryx, Coherus BioSciences, Daiichi Sankyo, Eisai, Eli Lilly, Gilead Sciences, Hospira, Idera, Immunomedics, ImmuPharma, Incyte, Invion, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Merck, MedImmune, Morphotek, Novo Nordisk, Novartis, Opexa Therapeutics, Principia, Regeneron, Sandoz, Sanofi, Santarus, Takeda, UCB, Vaccinex, Vertex Pharmaceuticals, and Vitae Pharmaceuticals.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Forms of vasculitis based on sizes of blood vessels affected
  • Pipeline landscape
    • Table Key clinical trials
  • Market landscape
    • Market overview
      • Table Global vasculitis treatment market snapshot
      • Table Global vasculitis treatment market 2016-2021 ($ millions)
      • Table Opportunity analysis in global vasculitis treatment market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by drug class
    • Table Market segmentation by drug class
    • Corticosteroids
      • Table Global vasculitis corticosteroid drugs market 2016-2021 ($ millions)
    • Immunosuppressants
      • Table Global vasculitis immunosuppressant drugs market 2016-2021 ($ millions)
    • Biologics
      • Table Global vasculitis biologics drugs market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of global vasculitis treatment market based on geography
    • Table Global vasculitis treatment market revenue by geography 2016-2021 ($ millions)
    • Vasculitis treatment market in Americas
      • Table Market scenario in Americas
      • Table Vasculitis treatment market in the Americas 2016-2021 ($ millions)
    • Vasculitis treatment market in EMEA
      • Table Market scenario in EMEA
      • Table Vasculitis treatment market in EMEA 2016-2021 ($ millions)
      • Table Opportunity analysis for EMEA
    • Vasculitis treatment market in APAC
      • Table Market Scenario of APAC
      • Table Vasculitis treatment market in APAC 2016-2021 ($ millions)
      • Table Opportunity analysis for APAC
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
      • Table Alternative therapies for vasculitis treatment
      • Table Adverse effects associated with vasculitis treatment
  • Market trends
    • Increase in public awareness programs
    • Strategic alliances
      • Table Alliances and agreements
    • Introduction of novel MOAs
      • Table List of few pipeline molecules with novel MOAs
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global vasculitis treatment market 2016
  • Key vendor analysis
    • Bristol-Myers Squibb
      • Table Bristol-Myers Squibb: Key highlights
      • Table Bristol-Myers Squibb: Strength assessment
      • Table Bristol-Myers Squibb: Strategy assessment
      • Table Bristol-Myers Squibb: Opportunity assessment
    • CELGENE
      • Table CELGENE: Strength assessment
      • Table CELGENE: Strength assessment
      • Table CELGENE: Strategy assessment
      • Table CELGENE: Opportunity assessment
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche: Key highlights
      • Table F. Hoffmann-La Roche: Strength assessment
      • Table F. Hoffmann-La Roche: Strategy assessment
      • Table F. Hoffmann-La Roche: Opportunity assessment
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report